Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 12, 2025
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)
Read more at globenewswire.comNASDAQ:AKRO (7/30/2025, 12:27:07 PM)
48.65
+1.16 (+2.44%)
Find more stocks in the Stock Screener
AKRO Latest News and Analysis
12 days ago - By: Chartmill
